Acquiring Company
EQT Private Equity
Acquired Company
Qiagen
LimburgFinancial ServicesVenture CapitalBiotechnologyDescription
EQT Private Equity, through Crown NL Bidco B.V., has agreed to acquire Qiagen for EUR 46.50 per share in cash, a deal valued at EUR 10.8 billion. Both Qiagen boards unanimously back the transaction and recommend that shareholders tender their stock. Closing is targeted for mid-2027, subject to regulatory clearances and a minimum acceptance threshold of 50% of shares plus one. The deal was agreed about a week before the October 23 SEC filing, and a law firm is reviewing board conduct tied to the sale.
Who to call at EQT Private Equity, and when
When EQT Private Equity changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day EQT Private Equity raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at EQT Private Equity, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at EQT Private Equity. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EQT Private Equity makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Qiagen?
Qiagen was acquired by EQT Private Equity. The deal was reported on October 30, 2026. EQT, Advent, and KKR & Co. are private equity firms that invest in various sectors, focusing on value creation through operational improvements and strategic growth. EQT Private Equity is privately held and operates in Financial Services.
When did EQT Private Equity acquire Qiagen?
EQT Private Equity's acquisition of Qiagen was reported on October 30, 2026. EQT Private Equity, through Crown NL Bidco B.V., has agreed to acquire Qiagen for EUR 46.50 per share in cash, a deal valued at EUR 10.8 billion. Both Qiagen boards unanimously back the transaction and recommend that shareholders tender their stock. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Qiagen do?
Qiagen is a German diagnostics group that supplies sample and assay technologies for molecular diagnostics and life sciences. The company is subject to a takeover offer of EUR 46.50 per share from EQT. It is privately held, operating in Biotechnology, and is based in Limburg.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.